Arcis Biotechnology Ltd.. (10/2/18). "Press Release: Arcis Biotechnology Raises £1.25 Million (USD $1.63 Million) Funding and Opens further £0.5 Million Investment Opportunity through Capital Cell". Daresbury.

	Organisation	Arcis Biotechnology Ltd.
	Group	Arcis:Altos (Group)
	Organisation 2	Capital Cell (GB)
	Product	nucleic acid extraction (technology)
	Product 2	crowdfunding
	Index term	Arcis:Altos–SEVERAL: investment, 201810 financing round £1.25m of Arcis Biotechnology from existing + new investors
	Index term 2	Arcis:Altos–SEVERAL: investment, 201810– crowd funding round targeting £0.5m of Arcis Biotechnology via Capital Cell
	Person	Whitehurst, Peter (Arcis:Altos 201810 CEO of Arcis Biotechnology)
	Person 2	O’Brien, Patrick (Capital Cell 201810 Investment Manager)

> £1.25 million already secured based on pre-money valuation of £18.2 million

> Additional funding will be used to further accelerate product development and company growth

Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced the closing of a £1.25 million investment round and a decision to overfund by an additional £0.5 million, via specialist life sciences equity crowdfunding platform Capital Cell. Arcis will use the funds to expand its innovative product range, and to support the continued growth of the company.

The £1.25 million in funding was secured from existing and new investors, based on a pre-money valuation of £18.2 million. Following its recent development successes in the isolation and preservation of microRNA (miRNA) and oncology biomarkers, Arcis is now looking to invest further in R&D, product development, and to drive international business expansion. The additional £0.5 million from the Capital Cell funding round will underpin the projected revenue growth and associated working capital requirements in the next two years. Previous investment includes an over-subscribed £2.5 million investment round in January 2016, and £160,000 under Innovate UK’s Biocatalyst programme.

Arcis’ product portfolio is based on its proprietary, rapid, two-step nucleic acid extraction and preservation technology, from a range of biological samples. The company has an extensive patent portfolio covering extraction and preservation of DNA and RNA for downstream processing by qPCR, RT-qPCR and sequencing. Arcis provides the system direct to customers as standalone kits, or through OEM sample preparation integration for assay development manufacturers. The speed, simplicity, and low resource requirements in comparison to competing technologies makes Arcis’ solution ideal for point-of-care, microfluidics or field-based testing.

Peter Whitehurst, CEO, Arcis Biotechnology, commented: “The Arcis technology has a strong IP portfolio, and has received a great deal of interest from commercial partners looking to negotiate a licence or OEM deal. We took the decision to work with Capital Cell due to their innovative approach, and their network of specialist life sciences investors. We look forward to working with the team to help fund the next exciting stage of Arcis’ development.”

Patrick O’Brien, Investment Manager, Capital Cell, said: “Arcis Biotechnology is being led by a highly experienced executive team, and has gained a strong foothold in the industry. We are delighted to be involved in the investment round.”

Details of the Arcis Biotechnology investment round can be found here: https://capitalcell.co.uk/campaign/arcis-biotechnology/

ENDS

Notes to editors

Media contact:

Katie Odgaard
Zyme Communications
Tel: +44(0) 7787 502 947
Email: katie.odgaard@zymecommunications.com

About Arcis Biotechnology (www.arcisbio.com)

Based at Sci-Tech Daresbury, one of the UK’s premier science parks, Arcis Biotechnology is focused on providing fast and convenient nucleic acid sample prep solutions. Obtaining genetic material from biological samples is a critical step which is often a time consuming and inefficient process. In less than three minutes, and with no prior sample preparation, the Arcis Sample Prep range of products allow users to quickly and conveniently go from cellular material to downstream nucleic acid investigation without the need for traditional isolation or purification. The process requires no laboratory equipment, and as little as 30µl of sample as starting material.

The Arcis technology, including two CE marked in vitro diagnostic products, can be used on many different samples containing DNA and RNA, including whole blood, plasma, urine, buccal swabs, and soil and plant extracts, and is particularly effective at isolating pathogens for detection.

Record changed: 2023-06-05